Patents by Inventor Lizhen Wu

Lizhen Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
    Patent number: 11358955
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: June 14, 2022
    Assignee: IMPACT THERAPEUTICS, INC.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof
    Publication number: 20190270732
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: IMPACT Therapeutics, Inc.
    Inventors: Sui Xiong CAI, Ye Edward TIAN, Haijun DONG, Qingbing XU, Lizhen WU, Lijun LIU, Yangzhen JIANG, Qingli BAO, Guoxiang WANG, Feng YIN, Chengyun GU, Xiuhua HU, Xiaozhu WANG, Sishun KANG, Shengzhi CHEN
  • 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
    Patent number: 10316027
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6, are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: June 11, 2019
    Assignee: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof
    Publication number: 20180215741
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6, are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: March 26, 2018
    Publication date: August 2, 2018
    Inventors: Sui Xiong CAI, Ye Edward TIAN, Haijun DONG, Qingbing XU, Lizhen WU, Lijun LIU, Yangzhen JIANG, Qingli BAO, Guoxiang WANG, Feng YIN, Chengyun GU, Xiuhua HU, Xiaozhu WANG, Sishun KANG, Shengzhi CHEN
  • 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP inhibitors and the use thereof
    Patent number: 9926304
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 27, 2018
    Assignee: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-Diones as PARP Inhibitors and the Use Thereof
    Publication number: 20160237070
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones represented by the Formula (I): wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 18, 2016
    Inventors: Sui Xiong CAI, Ye TIAN, Haijun DONG, Qingbing XU, Lizhen WU, Lijun LIU, Yangzhen JIANG, Qingli BAO, Guoxiang WANG, Feng YIN, Chengyun GU, Xiuhua HU, Xiaozhu WANG, Sishun KANG, Shengzhi CHEN
  • 3-aryl-6-aryl-[1,2,4]triazolo[4,3-?]pyridines as inhibitors of cell proliferation and the use thereof
    Patent number: 9199983
    Abstract: Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-a]pyridines thereof, represented by the Formula (I) wherein Ar1, Ar2, R1-R3 are defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: December 1, 2015
    Inventors: Suixiong Cai, Ye Edward Tian, Haijun Dong, Lei Chen, Zenghui Yu, Feng Yin, Sheng Bi, Lijun Liu, Lizhen Wu
  • 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
    Patent number: 9102631
    Abstract: Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula 1: wherein Ar, A, R1, R3-R6 are defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: August 11, 2015
    Assignee: IMPACT Therapeutics, Inc.
    Inventors: Suixiong Cai, Ye Edward Tian, Lizhen Wu, Lijun Liu, Xiaozhu Wang, Yangzhen Jiang, Guoxiang Wang, Xiuyan Zhang, Qingbing Xu, Zheng Meng
  • 1-(Arylmethyl)-5,6,7,8-tetrahydroquinazolline-2,4-diones and Analogs and the Use Thereof
    Publication number: 20140275711
    Abstract: Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula I, wherein Ar, A, B, R3-R6 are defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.
    Type: Application
    Filed: November 1, 2012
    Publication date: September 18, 2014
    Inventors: Suixiong Cai, Ye Edward Tian, Lizhen Wu, Lijun Liu, Xiaozhu Wang, Yangzhen Jiang, Guoxiang Wang, Xiuyan Zhang, Qingbing Xu, Zheng Meng
  • 1-(Arylmethyl)quinazoline-2,4(1H,3H)-diones as PARP Inhibitors and the Use Thereof
    Publication number: 20140023642
    Abstract: Disclosed are 1-(arylmethyl)quinazoline-2,4(1H,3H)-diones thereof, represented by the Formula (I) wherein Ar, R1-R6 are defined herein. Compounds having Formula (I) are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity.
    Type: Application
    Filed: March 31, 2012
    Publication date: January 23, 2014
    Applicant: Impact Therapeutics, Inc.
    Inventors: Sui Xiong Cai, Ye Edward Tian, Haijun Dong, Qingbing Xu, Lizhen Wu, Lijun Liu, Yangzhen Jiang, Qingli Bao, Guoxiang Wang, Feng Yin, Chengyun Gu, Xiuhua Hu, Xiaozhu Wang, Sishun Kang, Shengzhi Chen
  • 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof
    Publication number: 20130280245
    Abstract: Disclosed are 3-aryl-6-aryl-[1,2,4]triazolo[4,3-?]pyridines thereof, represented by the Formula (I) wherein Ar1, Ar2, R1—R3 are defined herein. Compounds having Formula (I) are inhibitors of cell proliferation. Therefore, compounds of the invention may be used to treat clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: November 16, 2011
    Publication date: October 24, 2013
    Applicant: IMPACT Therapeutics, Inc.
    Inventors: Suixiong Cai, Ye Edward Tian, Haijun Dong, Lei Chen, Zenghui Yu, Feng Yin, Sheng Bi, Lijun Liu, Lizhen Wu